Chronic Lymphocytic Leukemia Clinical Trial
Official title:
A Phase 1 Extension Study to Determine the Safety of UC-961 (Cirmtuzumab) at the Recommended Phase 2 Dose for Retreatment of Patients With Chronic Lymphocytic Leukemia Treated Previously With UC-961
Verified date | March 2019 |
Source | University of California, San Diego |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The purpose of the study is to investigate the safety of the investigational drug called
cirmtuzumab when given for a duration of 6 to 12 months. Cirmtuzumab is a type of drug called
a monoclonal antibody. This drug is designed to attach to a protein called ROR1 that is on
the surface of chronic lymphocytic leukemia (CLL) cells. This blocks growth and survival of
the CLL cells. ROR1 is rarely expressed on healthy cells so this drug should target the
cancer cells. Cirmtuzumab is considered experimental because its use is not approved by
United States (US) Food and Drug Administration (FDA).
Although there is evidence from tests on laboratory animals that cirmtuzumab can decrease the
number of CLL cells, the investigators do not know if this will work in humans. Therefore,
the goal of this study is to see if cirmtuzumab is safe and tolerable in study participants
when given for a duration of 6 to 12 months.
Status | Completed |
Enrollment | 3 |
Est. completion date | May 22, 2018 |
Est. primary completion date | February 27, 2018 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Clinical and phenotypic verification of B cell CLL and measurable disease. Immunophenotyping of the leukemic cells (blood or marrow) must demonstrate a monoclonal (or light chain positive) B cell population with immunophenotype consistent with CLL (e.g., co-expressing CD19 and CD5). - Recovered from toxic effects attributed to UC-961 to grade 1 levels, or baseline. - Must have measurable disease, including one of the following: - absolute lymphocyte count greater than 5000/uL - lymphadenopathy greater than 1.5 cm in longest dimension - splenomegaly - bone marrow biopsy with residual CLL cells, or resultant bone marrow dysfunction - Women of childbearing potential must agree not to become pregnant for the duration of the study. Both men and women must agree to use a barrier method of contraception for the duration of the study and until 10 weeks after the final dose of UC-961. - Subjects must have an ECOG performance status of 0-2. - Adequate hematologic function - Adequate renal function - Adequate hepatic function - Adequate coagulation tests Exclusion Criteria: - Pregnant or breast-feeding women - May have had intervening therapy since completion of initial UC-961 dosing, but excluding the following: - Within 7 days of UC-961 restart, or 5 half-lives (if known), whichever is shorter: small molecule tyrosine kinase inhibitor (eg: ibrutinib, idelalisib, AVL-292, IPI-145); - Within 28 days of UC-961 restart: chemotherapy (e.g., purine analogues, alkylating agents), corticosteroids, radiation therapy, or participation in any other investigational drug treatment (besides UC-961); - Within 56 days of UC-961 restart: previous UC-961 dosing; - Within 56 days of UC-961 restart: monoclonal antibody therapy directed against CLL (e.g., rituximab, ofatumumab, obinutuzumab, alemtuzumab). - Current infection requiring parenteral antibiotics. - Active infection with HIV, HBV, or HCV. - Concurrent malignancy or prior malignancy within the previous 3 years (other than completely resected carcinoma in situ, prostate cancer, or localized non-melanoma skin cancer). - Known central nervous system (CNS) involvement by malignancy. - Untreated autoimmunity such as autoimmune hemolytic anemia, or immune thrombocytopenia. - Uncompensated hypothyroidism (defined as TSH greater than 2x upper limit of normal not treated with replacement hormone). - Presence of more than 55% pro-lymphocytes in peripheral blood. Patients with Richter's transformation are not excluded. - Insufficient recovery from surgical-related trauma or wound healing. - Impaired cardiac function including any of the following: - Myocardial infarction within 6 months of starting study drug; - A past medical history of clinically significant ECG abnormalities; - Other clinically significant heart disease (e.g. uncontrolled congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen). |
Country | Name | City | State |
---|---|---|---|
United States | UC San Diego Moores Cancer Center | La Jolla | California |
Lead Sponsor | Collaborator |
---|---|
University of California, San Diego |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | Adverse events assessed by CTCAE v4.0 during treatment and 3 month follow-up | 1 year | |
Secondary | Overall response rate | 1 year | ||
Secondary | Progression free survival | 1 year | ||
Secondary | Stable Disease Rate (SD) | 1 year | ||
Secondary | Partial Response Rate (PR) | 1 year | ||
Secondary | Minimal Residual Disease Rate (MRD) | 1 year |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Enrolling by invitation |
NCT01804686 -
A Long-term Extension Study of PCI-32765 (Ibrutinib)
|
Phase 3 | |
Completed |
NCT02057185 -
Occupational Status and Hematological Disease
|
||
Active, not recruiting |
NCT04240704 -
Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL
|
Phase 1 | |
Recruiting |
NCT03676504 -
Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03280160 -
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab
|
Phase 2 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT00038025 -
A Study Of Deoxycoformycin(DCF)/Pentostatin In Lymphoid Malignancies
|
Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT05417165 -
Anti-pneumococcal Vaccine Strategy in Patients With Chronic Lymphocytic Leukemia
|
Phase 2 | |
Recruiting |
NCT04028531 -
Understanding Chronic Lymphocytic Leukemia
|
||
Completed |
NCT00001637 -
Immunosuppressive Preparation Followed by Blood Cell Transplant for the Treatment of Blood Cancers in Older Adults
|
Phase 2 | |
Completed |
NCT02910583 -
Ibrutinib Plus Venetoclax in Subjects With Treatment-naive Chronic Lymphocytic Leukemia /Small Lymphocytic Lymphoma (CLL/SLL)
|
Phase 2 | |
Completed |
NCT01527045 -
Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
|
Phase 2 | |
Recruiting |
NCT04679012 -
Polatuzumab Vedotin in Combination With Chemotherapy in Subjects With Richter's Transformation
|
Phase 2 | |
Recruiting |
NCT05405309 -
RP-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refractory Chronic Lymphocytic Leukemia
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT05023980 -
A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
|
Phase 3 | |
Recruiting |
NCT04553692 -
Phase 1a/1b Study of Aplitabart (IGM-8444) Alone or in Combination in Participants With Relapsed, Refractory, or Newly Diagnosed Cancers
|
Phase 1 | |
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|